Tris Pharma, Inc. Completes Its Facilities' Expansion, Receives FDA Clearance
SOUTH BRUNSWICK, N.J., Sept. 23 /PRNewswire/ -- Tris Pharma, a privately- owned, specialty pharmaceutical company, today announced that the expansion to its state-of-the-art research and manufacturing facility in South Brunswick is complete. This capacity-building initiative is a significant milestone for the company, marking its continued growth and success as a partner and provider of innovative drug delivery technologies.
The expansion provides approximately 15,000 square feet of additional space to the company's premises and current FDA-compliant cGMP facility. It allows for additional commercial-scale equipment and a new, larger warehouse that frees up space for a high-speed packaging area. This continued growth showcases Tris Pharma's momentum, and follows the company's successful clearance of its first FDA pre-approval inspection, which it passed without any deficiencies or 483s.
"These recent events show that the company is on a steady and stable path as charted," says Ketan Mehta, CEO and Founder of Tris Pharma. "FDA's assurance of our facilities and the recent investment in our capabilities means we have ample infrastructure with which to leverage our exciting pipeline of drug delivery technologies and services."
As pharmaceutical companies search for new ways to competitively differentiate their products, Tris Pharma's increased capacity enhances its position as a partner of choice and allows it to provide more value to companies seeking to expand their product portfolio or maximize their products' lifecycle.
"Tris Pharma's recent enhancements mean that now we can provide even more services to the pharmaceutical industry," says Scott Groner, Director of Regulatory Affairs and Compliance for Tris Pharma. "It also shows that, as our partners grow, we are growing along with them."
About Tris Pharma, Inc.
Tris Pharma, Inc. is a specialty drug delivery technology company. Tris specializes in controlled release dosage forms for liquid, solid and orally- disintegrating tablets; abuse-deterrent technology; and bioavailability enhancement of poorly absorbed drugs. Through its pharma partners, Tris has more than 30 products in development, submission or on market. Tris' research and manufacturing facilities are located in central New Jersey, USA. For more information, please visit www.trispharma.com
CONTACT: Nicole Wetzel of Tris Pharma, Inc., +1-732-940-2800,
nwetzel@trispharma.com
Web site: http://www.trispharma.com/